


EVID AI Data sheet 2023

EVID AI

Helping us to extract the up-to-date evidence you need from global medical literature...

- ✓ FASTER
- ✓ MORE EFFICIENTLY
- ✓ FROM A GREATER BREADTH OF SOURCES



- Are there situations in which you can't find answers to your **urgent scientific questions** in the time available?
- Do the results of your **literature search** still require the manual reviewing of, and data extraction from, vast quantities of papers?
- Can you be sure the answers you get from Google or any other search facility are **relevant and up to date**?

EVID AI provides us with the solution

15% MORE ARTICLES
AND 15x FEWER
IRRELEVANT ONES

59x FASTER
THAN MANUAL SEARCHES
USING PUBMED


HIGH QUALITY
RESULTS DEMONSTRATED
IN PUBLISHED LITERATURE

Our impactful **evidence synthesis** solutions are powered by a technology platform that unites **advanced artificial intelligence** with the very best in our **human research expertise**.



EVID AI is a unique AI-powered platform that provides the **world's largest, up-to-date database of healthcare literature results**, searching over 100 million data points to help our teams find the evidence you need.

Whether your query is part of a systematic literature review or an ad hoc question addressing a business-critical situation, EVID AI can search **PubMed** and any **custom sources** you wish, before offering a range of filtering options based on that specific criterion, and then a shortlist of results.

1. EVID AI supports both simple and Boolean searches using the same modifiers as PubMed.



- 2.** The AI creates filtering options specific to the search undertaken. **3.** The user is presented with carefully curated results.



However, EVID AI is far more than just an AI-curated literature search tool. Employing **machine reading** and **semantic understanding** to locate data within an abstract, it categorizes the language around it and then extracts and presents the data in **structured evidence tables** in a transparent and verifiable manner.


- 4.** Machine learning is applied to extract data from the text and place it into structured evidence tables.

1 Unstructured text (sentences) processed by our AI

Results: Guselkumab was superior ($P < .001$) to placebo at week 16 (85.1% vs 6.9% [Investigator Global Assessment score of 0/1 (cleared/minimal)] and 73.3% vs 2.9% [90% or greater improvement in PASI score from baseline (PASI 90)]). Guselkumab was also superior ($P < .001$) to adalimumab for Investigator Global Assessment 0/1 and PASI 90 at week 16 (85.1% vs 65.9% and 73.3% vs 49.7%), week 24 (84.2% vs 61.7% and 80.2% vs 53.0%), and week 48 (80.5% vs 55.4%) and 76.3% vs 47.9%). Furthermore, guselkumab significantly improved patient-reported outcomes through week 48. Adverse event rates were comparable between treatments.

What do these values refer to?

2 The AI assesses up to 25 million articles an hour, structuring the data



5. Often in just a matter of minutes, EVID AI will produce transparent, reproducible, and exportable results. The tables immediately provide the user with the data they need without the need to review individual abstracts.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial (2017)

Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB

Journal of the American Academy of Dermatology, 3, 405-417.

Source: PubMed Subject: Human Trial Intervention Prospective Drug Therapy phase 3 double blind

[Manage paper data](#)

Guselkumab was also superior ($P < .001$) to adalimumab for Investigator Global Assessment 0/1 and Psoriasis Area and Severity Index 90 at week 16 (85.1% vs 65.9% and 73.3% vs 49.7%), week 24 (84.2% vs 61.7% and 80.2% vs 53.0%), and week 48 (80.5% vs 55.4% and 76.3% vs 47.9%).

Result	Intervention/Group	Outcome
284 of 334	Guselkumab	for Investigator Global Assessment 0/1, at week 16
220 of 334	adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47	for Investigator Global Assessment 0/1, at week 16
245 of 334	Guselkumab	Psoriasis Area and Severity Index 90, at week 16
166 of 334	adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47	Psoriasis Area and Severity Index 90, at week 16
281 of 334	Guselkumab	for Investigator Global Assessment 0/1 at, week 24
206 of 334	adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47	for Investigator Global Assessment 0/1, week 24
268 of 334	Guselkumab	Psoriasis Area and Severity Index 90 at, week 24

Where AI and evidence synthesis expertise meet

EVID AI does not replace human expertise, it enhances it. Together with the client, we frame the question and interpret the results, but the AI – supported by our expert teams – does the heavy lifting for data gathering, leaving your scientists free to focus their time and expertise on **evaluating and communicating** the evidence they find.

Already used by us on behalf of some of the world’s **leading pharmaceutical companies**, contact us to find out what EVID AI can do for you and your team.

“
EVID’s ability to review conference data and allow us to filter on study types and outcomes saved us weeks of manual effort, especially important for this urgent update.
 ”
Pharma Client

Ask us about Genesis Research’s AI-powered evidence synthesis solutions.

[WATCH A PRESENTATION](#)

[BOOK A PRIVATE DEMO](#)

solutions@genesisrg.com

[REVIEW THE LITERATURE](#)

[ASK A QUESTION](#)

solutions@genesisrg.com



Evidence Strategy

- HEOR and RWE Strategic Planning
- Value Proposition Development
- Stakeholder Advisory Boards and Payer Panels
- HTA/ICER Support
- Rapid Payer Response™



Evidence Generation

- Claims and EHR Database Analyses
- External Control Arms
- Meta-analysis and Indirect Treatment Comparisons
- Targeted and Systematic Literature Reviews
- Economic Modeling
- Outcomes-based Contracting



Evidence Optimization

- EVID AI Platform: Technology-assisted Evidence Synthesis
- RWE Interactive Data Dashboards
- Evidence Management Platforms
- RWE Automation



Evidence Communication

- Value Dossiers
- Manuscripts, Abstracts, and Posters
- Evidence Slide Decks for MSL and Commercial Teams
- HTA Submissions



Ask us how our agile, integrated approach can help you find **a better way.**

genesisrg.com | +1 888-503-2680